Since GP88 mediated estrogen-independence and conferred anti-estrogen therapy resistance to ER+ breast cancer, we focused this investigation on ER+ breast tumors in order to determine whether GP88 expression is a prognostic factor in ER+ non metastatic IDC. The gene discussed is ESR1; the disease is breast carcinoma.